药物治疗对注意缺陷多动障碍儿童生活质量的影响

doi:10.11852/zgetbjzz2018-26-05-14

摘要/Abstract

摘要： 生活质量(QOL)是指个体的健康状态对其生理功能、心理功能和社会功能方面的影响。在临床工作及研究中,QOL可以作为评估行为、功能和治疗效果的一种手段,促进对疾病更全面的了解。注意缺陷多动障碍(ADHD)是一种神经发育障碍,研究显示ADHD患儿的QOL显著降低,改善ADHD患儿的QOL具有重要治疗意义。本文介绍了ADHD患儿QOL的临床特点,重点介绍了药物对ADHD患儿QOL 的作用,并提出了未来改善ADHD患儿QOL的方向。

关键词: 注意缺陷多动障碍, 生活质量, 评估量表, 药物, 儿童

Abstract: Quality of life (QOL) refers to the influence of individual health status on its physiological function, psychological function and social function. In clinical work and research, QOL can be used as a way of assessing behavior, function, and treatment to promote more comprehensive understanding of the disease. Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder. Studies have shown that QOL of ADHD children significantly reduced, and improving the QOL of ADHD children has important therapeutic significance. This review describes the clinical features of QOL in children with ADHD, focusing on the role of drugs in ADHD children′ QOL, and giving future direction of QOL improvement in ADHD children.

Key words: attention deficit hyperactivity disorder, quality of life, evaluation scale, drugs, children

中图分类号:

R179

赵泾泾综述, 徐通, 周翊审校. 药物治疗对注意缺陷多动障碍儿童生活质量的影响[J]. 中国儿童保健杂志, 2018, 26(5): 513-517.

ZHAO Jing-jing, XU Tong, ZHOU Yi. Effects of drugs on quality of life in children with attention deficit hyperactivity disorder[J]. journal1, 2018, 26(5): 513-517.

参考文献

[1] Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis[J]. Epidemiol,2014,43(2):434-442.
[2] Bron T,Bijlenga D,Verduijn J. Prevalence of ADHD symptoms across clinical stages of major depressive disorder[J].J Affect Disord, 2016,197(1):29-35.
[3] Adamo N, Seth S, Coghill D. Pharmacological treatment of attention-deficit hyperactivity disorder: assessing outcomes[J]. Expert Rev Clin Pharmacol, 2015,8(4):383-397.
[4] VelöS, Keresztény A, Szentiványi D,et al. Quality of life of patients with attention-deficit/hyperactivity disorder: systematic review of the past 5 years[J]. Neuropsychopharmacol Hung, 2013,15(2):73-82.
[5] Montoya A, Quai D,Anand E,et al. Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention deficit/hyperactivity disorder, based on a pooled analysis[J]. ADHD Atten Def Hyp Disord, 2014, 6(1):25-34.
[6] Coghill D,Banaschewski T,Soutullo C. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder[J]. Eur Child Adolesc Psychiatry,2017,26(11):1283-1307.
[7] Schei J, Novik TS, Thomsen PH, et al. Improved quality of life among adolescents with attention-deficit/hyperactivity disorder is mediated by protective factors: a cross sectional survey[J]. BMC Psychiatry, 2015, 15:108.
[8] Marques JC, Oliveira JA,Goulardins JB, et al. Comparison of child self-reports and parent proxy-reports on quality of life of children with attention deficit hyperactivity disorder[J]. Health Qual Life Outcomes, 2013, 11:186.
[9] Coghill D,Hodgkins P. Health-related quality of life of children with attention-deficit hyperactivity disorder versus children with diabetes and healthy controls[J]. Eur Child Adolesc Psychiatry,2016,25(3):261-271.
[10] Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder[J]. Qual Life Res, 2011, 20(5):691-702.
[11] Danckaerts M,Sonuga-Barke EJS,Banaschewski T,et al. The quality of life of children with attention deficit hyperactivity disorder:a systematic review[J]. Eur Child Adolesc Psychiatry, 2010,19(2):83-105.
[12] Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder[J]. CNS Drugs, 2014,28(12):1191-1203.
[13] Dell′Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention deficit hyperactivity disorder and comorbid oppositional defiant disorder:a placebo-controlled Italian study[J]. Eur Neuropsychopharmacol, 2009,19(11):822-834
[14] CoghillD.The impact of medications on quality of life in attention-deficit hyperactivity[J]. CNS Drugs, 2010, 24 (10): 843-866.
[15] Berek M, Kordon A, Hargarter L, et al.. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?[J]. Child Adolesc Psychiatry Men Health, 2011, 5:26.
[16] Hodgkins P, Shaw M, McCarthy S. The pharmacology and clinical outcomes of amphetamines to treat ADHD:does composition Matter?[J]. CNS Drugs, 2012, 26 (3): 245-268.
[17] Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention deficit-hyperactivity disorder: results from a Taiwanese sample[J]. Aust NZJ Psychiatry,2007, 41(12):998-1004
[18] Wehmeier PM, Schacht A, Escobar R, et al.Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit/hyperactivity disorder core symptoms: META-analysis of five atomoxetine trials[J]. Child Adolesc Psychiatry Ment Health, 2010, 4:30
[19] Savill NC,Buitelaar JK, Anand E,et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder:A comprehensive review of over a decade of clinical research[J]. CNS Drugs, 2015, 29(2):131-151.
[20] Escobar R,Schacht A,Wehmeier P, et al. Quality of life and attention deficit hyperactivity disorder core symptoms[J]. J Clin Psychopharmacol, 2010,30(2),145-151.
[21] Prasad S,Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)[J]. Curr Med Res Opin, 2007,23(2):379-394.
[22] Haynes H. Attention-deficit/hyperactivity disorder under treatment outcomes research (AUTOR): a European observational study in pediatric subjects ADHD[J].Atten Def Hyp Disord, 2015, 7(4):295-311.
[23] Cannon M, Pelham WH, Sallee FR, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder[J]. Child and Adolescent Psychopharmacology, 2009,19(5):511-517.